AxoGen, Inc. (NASDAQ:AXGN) - Equities research analysts at Wedbush cut their Q3 2017 EPS estimates for shares of AxoGen in a research report issued to clients and investors on Thursday. Wedbush analyst Levy. T now expects that the medical equipment provider will post earnings of ($0.10) per share for the quarter, down from their previous estimate of ($0.09). Wedbush has a “Outperform” rating and a $14.00 price target on the stock. Wedbush also issued estimates for AxoGen’s Q4 2017 earnings at ($0.14) EPS, FY2017 earnings at ($0.42) EPS, FY2018 earnings at ($0.22) EPS and FY2019 earnings at $0.10 EPS.
AxoGen (NASDAQ:AXGN) last released its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. The business had revenue of $15.20 million during the quarter, compared to the consensus estimate of $14.40 million. AxoGen had a negative return on equity of 114.64% and a negative net margin of 27.50%. The business’s revenue was up 46.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.09) EPS.
TRADEMARK VIOLATION WARNING: “AxoGen, Inc. (AXGN) to Post Q3 2017 Earnings of ($0.10) Per Share, Wedbush Forecasts” was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://stocknewstimes.com/2017/08/18/axogen-inc-axgn-to-post-q3-2017-earnings-of-0-10-per-share-wedbush-forecasts-updated.html.
Several other equities research analysts also recently commented on the company. Cantor Fitzgerald initiated coverage on AxoGen in a report on Thursday, June 29th. They set an “overweight” rating and a $18.00 target price for the company. ValuEngine raised AxoGen from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. BidaskClub downgraded AxoGen from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Finally, Leerink Swann initiated coverage on AxoGen in a report on Monday, July 31st. They set an “outperform” rating and a $22.00 target price for the company. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $15.90.
AxoGen (NASDAQ AXGN) opened at 14.65 on Monday. The stock’s 50 day moving average price is $15.87 and its 200 day moving average price is $12.68. AxoGen has a 1-year low of $6.51 and a 1-year high of $17.25. The firm’s market cap is $486.97 million.
A number of large investors have recently made changes to their positions in the company. Russell Investments Group Ltd. increased its stake in shares of AxoGen by 238.7% in the second quarter. Russell Investments Group Ltd. now owns 611,678 shares of the medical equipment provider’s stock valued at $10,245,000 after buying an additional 431,057 shares in the last quarter. Lyon Street Capital LLC acquired a new stake in shares of AxoGen during the first quarter valued at about $2,166,000. Renaissance Technologies LLC acquired a new stake in shares of AxoGen during the first quarter valued at about $1,473,000. Gilder Gagnon Howe & Co. LLC increased its stake in shares of AxoGen by 26.5% in the first quarter. Gilder Gagnon Howe & Co. LLC now owns 559,516 shares of the medical equipment provider’s stock valued at $5,847,000 after buying an additional 117,178 shares in the last quarter. Finally, Summit Partners Public Asset Management LLC increased its stake in shares of AxoGen by 27.4% in the first quarter. Summit Partners Public Asset Management LLC now owns 409,498 shares of the medical equipment provider’s stock valued at $4,279,000 after buying an additional 88,140 shares in the last quarter. 64.58% of the stock is owned by hedge funds and other institutional investors.
Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
